SIRT1 and prostate cancer: ZEB1 can also recruit the class III HDAC SIRT1 to silence E-cadherin and promote EMT and metastasis in prostate cancer cells, and the authors suggested the use of SIRT1 inhibitor as therapeutic strategy against metastasis cascade [143].